Kornimate/medical-research-clean huggingface dataset:
measurement of high order aberrations in late stages keratoconus

Conditions: Keratoconus

Summary: the instrument that will be used in the study is the murcia monocular adaptive optics visual simulator (aovis-i). the system provides an objective characterization of the optical quality of the patient's eye by application of wave-front sensing technology. the optical condition of every eye is represented by its wave aberration. this characterization overcomes the current description based only in refractive errors. this provides an accurate description of the optics of the eye based on the assessment of the whole set of ocular aberrations. the particular wave-front sensor is of a hartmann-shack type. one characteristics of this wave-front sensor is its high dynamic range allowing measuring highly aberrated eyes, such as patients with keratoconus.

the complete procedure in one patient takes less than 5 minutes and is completely non-invasive.

Eligibility criteria:
inclusion criteria: * to be able to understand an information and give a consent * patients over 18 * patients with keratoconus * affiliated to medical insurance. exclusion criteria: * non keratoconus patients * patients under 18 * pregnant women or nursing mothers * ocular surgery 90 days before inclusion * ocular infection * keratitis * restless patients

Keywords: keratoconus, wave-front sensing technology, aberrometer
acute myocardial infarction by penetrating cardiac trauma

Conditions: Myocardial Infarction

Summary: patients with a cardiac stab wound could be complicated by a posttraumatic acute myocardial infarction (pami). traditionally, the investigators can explain it by the occlusion of a coronary artery; but the pami isn´t constantly related with coronary artery injuries or their damage in the cardiac injury repair. the investigators objectives are to know the pami incidence, make an approximation to pami pathophysiology, and propose management strategies.


Eligibility criteria:
inclusion criteria: * heart stab injury exclusion criteria: * previous cardiac injuries, coronary artery disease with previous diagnostic, previous coronary angiography (for any indication)

Keywords: heart injuries posttraumatic myocardial infarction echocardiography coronary angiography
management of heart failure in italian outpatients clinics: observational study

Conditions: Heart Failure

Summary: optima-hf is an observational, cross-sectional, multicenter, real-life study conducted in two different clinical settings: hf outpatients' clinics of italian university hospitals and territorial cardiology outpatients' services. aim of the optimization of therapy in the italian management of heart failure \[optima-hf\] registry is to collect data on hf patients followed in different italian outpatients' settings to describe the current italian population of hf patients, in terms of demographic characteristics and disease features, with a specific focus on guideline-directed medical therapy (gdmt) prescription, assessing its improvement after educational activities. in the present analysis we report the baseline data on the general enrolled population with a specific focus on hfref treatment adherence and prescription rates, according to the most recent european guidelines.


Eligibility criteria:
inclusion criteria: age \>18 years, post-menopausal, permanent sterile, or childbearing potential on highly effective contraceptive methods women, stable clinical conditions (nyha class i-iii), outpatients setting, capability to understand the study procedures and sign the informed consent form. exclusion criteria: any clinical condition that would have jeopardized patient safety while participating in this study.
rural asthma effectiveness study

Conditions: Asthma

Summary: the investigators will test if their intervention, asthma self-management for adolescents (asma), an 8-week, high school-based intervention for teenagers, improves asthma in rural high school students with uncontrolled asthma when delivered by chws. the investigators will also test the cost-effectiveness of asma, and examine the barriers and facilitators of asma's widespread implementation.

asthma, the most common pediatric chronic illness, has high prevalence and morbidity among adolescents. despite this, there are few interventions for high school students, and none have been tested when delivered by community health workers (chws) or in rural areas. this represents a significant limitation because the chw model has been shown to be successful in clinic- and home-based interventions. also, rural adolescents with asthma represent a very large population. given the high prevalence of asthma in this group, this oversight is a significant public health concern. cost effectiveness analyses and implementation research are also lacking in asthma intervention research. this study addresses these treatment and methodological gaps. the investigators developed and established the efficacy of asthma self-management for adolescents (asma), an 8-week, high school-based intervention, in urban hispanic and african american adolescents.

Eligibility criteria:
inclusion criteria: * adolescents who are at least 13.0 at the time of consent * teenager reports having a prior asthma diagnosis, and in the last 12 months has: (a) used prescribed asthma medication and (b) uncontrolled asthma, defined as: (i) symptoms 3+ days a week; (ii) night awakenings 3+ nights per month; (iii) 2+ ed visits; or (iv) 1+ hospitalization for asthma; and * adolescents are english proficient exclusion criteria: • co-morbid diseases that affect lung functioning.

Keywords: asthma self-management for adolescents (asma) community health workers (chw)
comparison of demographic data mentioned by the patients or measured by a physician

Conditions: Obstructive Sleep Apnea

Summary: osa (obstructive sleep apnea) represents a major risk of postoperative complications. predictive scores have been developed as the stop-bang score and the des-osa score. these scores take into account morphological parameters such as weight, height, and neck circumference. these data can be contained from the patients (self-reported) or by the measurements performed by a physician. the aim of this study is to compare the accuracy of both measurements (self-reported by the patient or measured by the physicians).


Eligibility criteria:
inclusion criteria: * all patients scheduled for elective surgery on a one-day hospital exclusion criteria: * patient refusal
utilizing the trunk as a proximal lever to strengthen the hip musculature and alter lower extremity function

Conditions: Patellofemoral Pain Syndrome

Summary: does a rotary based triplanar exercise intervention that utilizes the trunk as a proximal lever, strengthen the hip and alter dynamic le alignment in running females?

current hip-focused programs fail to alter hip adduction angles in females while performing higher speed and more complex maneuvers such as running. (willy, et al., 2011) - 10 female runners, underwent 6 wk. hip focused intervention, change in sls but no change in hip adduction angle while running. a different intervention strategy that includes utilizing the trunk as the proximal lever to strengthen the hip, could potentially alter biomechanical outcomes such as hip adduction angles in female runners. this study will apply a new intervention model and then measure running, single leg squat and hip strength to determine if a newly informed intervention can alter le kinematics in females while running and make improvements in hip strength following the intervention inclusion criteria * 18 years old or greater * female exclusion criteria * injury of the lumbar spine, hips, knees or foot/ankle in the last 6mos that required medical attention * any surgery of the lower back or the pelvis or lower extremities any time in the subjects life

Eligibility criteria:
inclusion criteria: * 18\> year old female; must be able to run on the treadmill for 5-7 min and perform a single leg squat exclusion criteria: * surgery to the lb or lower extremities significant injury (seeking medical attention) to the lb or les in the last 6mos.

Keywords: knee hip exercise proximal control pfps
a study of krn23 in subjects with x-linked hypophosphatemic rickets/osteomalacia

Conditions: X-linked Hypophosphatemic Rickets/Osteomalacia

Summary: the objective of this study is to assess the safety and tolerability of krn23 after a single subcutaneous (sc) administration in subjects with x-linked hypophosphatemic rickets/osteomalacia (xlh) in japan or korea.


Eligibility criteria:
inclusion criteria: 1. 18 years or older 2. patients with xlh exclusion criteria: 1. have an active infection or chronic inflammatory disease 2. have uncontrolled hypertension 3. have uncontrolled diabetes mellitus 4. history of known immunodeficiency 5. use of a pharmacologic vitamin d metabolite or its analogs within 21 days prior to screening and after screening 6. use of phosphate, calcium preparation, calcimimetics, aluminum hydroxide antacids, thiazide diuretic, acetazolamide, or phosphate, calcium, and/or vitamin d-containing supplements within 10 days prior to screening and after screening 7. pregnant or lactating females, women who are possibly pregnant or patients who have no intention of utilizing adequate contraception

Keywords: xlh
trachoma elimination follow-up

Conditions: Trachoma; Chlamydia

Summary: the who has initiated a program to eliminate blinding trachoma by the year 2020, in large part by mass oral azithromycin distributions. it is not clear how frequently or for how long these treatments are necessary. here we assess the frequency and duration of treatment.

40 villages in the gurage zone of ethiopia were randomly assigned to biannual treatment, annual treatment, and a single treatment. each treatment consisted of a single dose of oral azithromycin to the entire population over the age of 1 year (when the study was started, azithromycin had not yet been approved for ages below 1 year). we assess the prevalence the ocular chlamydia that causes trachoma in the peak prevalence age of 1-5 years at baseline, and 2, 6, 12, 18, and 24 months post treatment. an extension of the study monitors infection at 30 and 36 months post treatment. untreated villages from the same area are enrolled in a step-wedge design to assess the presence of a secular trend. a random sample of those not within the 1-5 year old age group are examined to assess the prevalence of infection in the entire community.

Eligibility criteria:
inclusion criteria: age 1 to 5 years old in a village in the gurage zone with endemic trachoma exclusion criteria: refusal of village chief (for village inclusion), or refusal of parent or guardian (for individual inclusion)

Keywords: trachoma chlamydia azithromycin
correction of lower limb deformities with fixator assisted nailing

Conditions: Deformity; Bone

Summary: it is a retrospective study at a tertiary care hospital. all cases of lower limb deformity whose correction was done with fixator assisted im nailing from 2010 till 2017 were analyzed.

it is a retrospective study at a tertiary care hospital. all cases of lower limb deformity whose correction was done with fixator assisted im nailing from 2010 till 2017 were analyzed. pre op x-rays and post op x rays will be analyzed for mechanical axis deviation (mad), anatomical lateral distal femoral angle (aldfa), mechanical lateral distal femoral angle (mldfa) and medial proximal tibial angle (mpta), post-operative activity and functional status of the patients. data will be analyzed using spss

Eligibility criteria:
inclusion criteria: - all those patients who underwent fixator assisted intramedullary nailing of tibia or femurs for deformity correction were included exclusion criteria: * patients who lost to follow up and those with missing records were excluded from the study.
col4a1 gene related cerebra-retinal angiopathy

Conditions: Cerebra-retinal Angiopathy

Summary: this prospective multicenter cohort study aims to define the clinical, radiological and mutational spectrum of the disease related to col4a1 gene.

150 index patients (children or young adult) will be prospectively recruited over three years according to eligibility criteria. relatives will be also recruited. clinical, brain mri-mra and genetic testing (col4a1 mutation screening) will be conducted for each included patient or asymptomatic relatives. 13 french investigating centres will be participating to the study.

Eligibility criteria:
inclusion criteria: inclusion criteria for the index patient : * children and young adult (\< 65 years) * intracranial hemorrhage of unknown etiology * leukoencephalopathy * any associated signs (including retinal arteriolar tortuosity, intracranial aneurysm, porencephaly, infantile cerebral palsy, juvenile cataract) exclusion criteria: (for the index patient) * hypertension * diabetes * other (than col4a1) genetic small vessel diseases of the brain

Keywords: genetic cerebral angiopathy retinal angiopathy col4a1 gene infantile cerebral palsy congenital porencephaly congenital cataract leukoencephalopathy col4a1 gene related cerebra-retinal angiopathy
a study of safety and efficacy of infliximab (remicade) in patients with copd

Conditions: Chronic Obstructive Pulmonary Disease; COPD

Summary: the purpose of this study is to evaluate the safety and effectiveness of infliximab (remicade) in patients with chronic obstructive pulmonary disease (copd). infliximab (remicade) targets specific proteins in the body's immune system to help control the development of inflammation to help reduce painful disease.

chronic obstructive pulmonary disease (copd) is a smoking-related inflammatory lung disease that results in reduced lung function, causing the symptoms or problems that you have when breathing. copd includes both chronic bronchitis and emphysema. the symptoms of copd are cough, sputum (phlegm) production, breathlessness, and wheezing. advanced disease may also involve changes in appetite and weight loss. the drug used in this study is called remicadeâ, and the active component is called infliximab. infliximab binds to and blocks the activity of a naturally occurring substance in the body called tumor necrosis factor alpha or tnfa, which may be associated with inflammation and a decrease in lung function.the purpose of this study is to evaluate the safety and effectiveness of infliximab in the treatment of patients with symptoms of moderate to severe copd.patients will be receive infusions of either placebo, 3 mg/kg infliximab or 5mg/kg infliximab at weeks 0, 2, 6, 12, 18, and 24.safety evaluations will be performed at specified intervals throughout the study and will consist of laboratory tests, vital signs (such as blood pressure), physical examinations and the occurrence and severity of adverse events as well as other study specific procedures. patients will receive infusions of either placebo, 3 mg/kg infliximab or 5mg/kg infliximab at weeks 0, 2, 6, 12, 18, and 24.

Eligibility criteria:
inclusion criteria: * patients must have moderate or severe copd * patients must have at least one episode of copd-related symptoms (eg, cough, sputum production, shortness of breath) within 2 months prior to screening exclusion criteria: * patients must not have asthma as main component of obstructive airway disease * patients must not have had a moderate or severe exacerbation of copd within previous 1 month

Keywords: chronic obstructive pulmonary disease copd infliximab remicade
auditory mmn eeg in trd in response to ketamine

Conditions: Treatment-resistant Depression (TRD)

Summary: to develop and test a neurocomputational model of ketamine treatment response predictions in trd.

the investigators propose applying a previously validated computational model of the mmn and the ensuing effects of nmdar antagonism to predict treatment response following ketamine infusions in trd patients and distinguish ketamine's antisuicidal effects from those related to mood improvements. the study has two subgoals: first, the computational mechanisms underlying mmn reductions that predict ketamine treatment response in trd patients will be examined. second, the computational mechanisms will be linked to their underlying neural causes using neural circuit models. beyond understanding ketamine's short- and long-term mechanisms of action in trd, the parameters obtained from fitting these models to noninvasive eeg recordings may facilitate single-patient treatment predictions. if successful, this approach may provide clinically useful prognostic statements in individual patients.

Eligibility criteria:
inclusion criteria: 1.18 to 65 years of age 2. meeting diagnostic and statistical manual for mental disorders (dsm-5) criteria for mdd and in a major depressive episode and ≥10 on the montgomery-asberg depression rating scale (madrs). 3. competent to consent-based on their ability to provide a spontaneous narrative description of the key elements of the study. 4. failure of at least two trials of antidepressant therapy during the current episode (treatment-resistant depression) and receiving ketamine treatment clinically as administered by their clinician 5. staying on stable dosages of any concomitant psychotropic medications. exclusion criteria: 1. history of bipolar disorder or psychosis 2. current substance use or history of substance use during the past year (excluding nicotine and caffeine use disorder) 3. concomitant major and unstable medical or neurologic illness or a history of seizures. 4. non-english-speaking individuals.
helix, a double-masked study of syl1001 in patients with moderate to severe dry eye disease (ded)

Conditions: Dry Eye Disease

Summary: the purpose of this study is to determine whether syl1001 ophthalmic solution is safe and effective in the treatment of signs and symptoms of dry eye disease.


Eligibility criteria:
inclusion criteria: * both genders * ≥ 18 years old * give written informed consent to participate in the study after having been informed of the study design, objectives and possible derived risks * common symptoms of persistent, daily, moderate to severe dry eye lasting more than six months. * use of artificial tears * vas scale for eye discomfort/pain between 30 - 80 * cfs ≥ 2 and ≤ 4 on the oxford scale * tbut \< 10 seconds * hyperemia score ≥ 1 (mcmonnies scale) * schirmer's test without anesthesia ≥ 2 and \< 10 mm/5min in the eye * corrected visual acuity ≥ 0.7 logmar exclusion criteria: * pregnant or breastfeeding females or those with a positive pregnancy test. * females of childbearing potential who will not use a medically acceptable contraceptive method from selection and during the whole study. * current relevant disease, including respiratory disease, cardiovascular, endocrine, neurological, haematological, renal, neoplasic, hepatopathy, gastrointestinal distress, hypertension, or infectious acute processes. * past history of a chronic o recurring condition that could interfere with study according to the investigator's judgement. * concomitant use of other drugs with analgesic activity by any route of administration at the enrolment period. * changes in any ocular and/or systemic concomitant medication one month prior to the study commencement and during the study development. * changes on the preestablished artificial tears dosage 15 days prior to the study commencement and during the study development. * cyclosporine treatment initiation or changes in cyclosporine dosage or dosing regimen during the 6 months prior to enrolment. * previous history of drug hypersensitivity. * use of contact lenses * case history of drug or alcohol abuse or dependence. * relevant abnormal laboratory results as judged by the investigator * previous refractive surgery * participation in a clinical trial within 2 months before the enrolment visit * relevant ocular pathology judged by the investigator.

Keywords: syl1001 sirna
subjective study to assess the efficacy of apd125 in patients with sleep maintenance insomnia

Conditions: Primary Insomnia

Summary: this study is designed to compare 2 doses of apd125 (20 mg and 40 mg) with placebo in otherwise healthy adults with primary insomnia primarily with complaints of maintaining sleep. participants will be required to maintain a daily sleep dairy for up to 3 weeks while on study.


Eligibility criteria:
inclusion criteria: * men and women, ages 18 to 65 years * primary insomnia as defined in dsm-iv-tr, with predominant complaint of impaired sleep maintenance and confirmed by patient reported sleep diaries * generally good health exclusion criteria: * history of any sleep disorder, other than primary insomnia (e.g., restless leg syndrome, narcolepsy, sleep apnea, and disorders of rem/nrem sleep) * any clinically significant medical condition, laboratory finding, or ecg finding * pregnant and/or lactating females * history of substance abuse within 2 years or positive urine drug screen * positive hepatitis b/c results or hiv markers * history of treatment with an investigational drug within the last month * recent travel involving crossing more than 3 time zones or plans to travel to another time zone (\> 3 time zones) during the study

Keywords: insomnia sleep maintenance insomnia sleep quality non-restorative sleep multiple awakenings
gallium-68 dotatoc for management of neuroendocrine tumors

Conditions: Neuroendocrine Tumors

Summary: gallium-68 dotatoc is a material used to find neuroendocrine tumors (nets) using positron emission tomography (pet scan). the material has already been shown to be better than the currently available imaging agents. this study is designed to evaluate the clinical impact of pet ct scanning using this agent in the evaluation and management of patients with nets.

patients with nets will be evaluated by their own physicians. before doing the pet scan using gallium-68 dotatoc, the physicians will be asked to describe the type of treatment that they would recommend. after the test is performed and the result reviewed, the physician will be asked to reevaluate the therapeutic and management options. data will be analyzed to determine the impact of the testing on patient management. gallium-68 has been designated an "orphan drug" due to the relative rarity of nets. it is expected that the data collected from this and other similar trials will be used to provide data to the fda regarding the safety and efficacy of this drug as an imaging agent for nets and ultimately lead to fda approval.

Eligibility criteria:
inclusion criteria: * proven or suspected neuroendocrine tumor physician referral for imaging exclusion criteria: * pregnancy

Keywords: neuroendocrine tumor carcinoid tumor